PATIENT-REPORTED OUTCOME MEASURES (PROMs)
Patient-Reported Outcome Measures (PROMs) are validated tools for self-evaluation of health characteristics. Some PROMs used for urticaria include the UAS and the UCT. These PROMs contain exactly the questions you answer daily in the CRUSE® app. PROMs are vital tools for your treating physician. CRUSE® makes it easy to answer the daily questions allowing you to do this on your mobile device instead of paper.
Get CRUSE® here
Learn more about the importance of using PROMs by listening to episode 3 of “All Things Urticaria” podcast via Spotify or via Apple Podcast.
Disease activity
Urticaria Activity Score (UAS) & Angioedema Activity Score (AAS)
There are two PROM tools to measure urticaria activity:
The UAS is a validated PROM tool for urticaria patients to self-evaluate disease activity. It also helps the treating physician to assess treatment success. The UAS is based on a daily questionnaire recording the number of wheals and itch intensity summed to give a daily score.
Lower scores and higher scores represent low and high disease activity, respectively. UAS7, UAS28, and UAS84 describe the disease activity of 7, 28, and 84 consecutive days. As urticaria symptoms often change in intensity, it is essential that patients document their symptoms continuously using the UAS.
The UAS7 requires complete documentation for 7 consecutive days, as this is what makes assessment of disease activity possible. For a more detailed and comprehensive assessment of disease activity, the UAS28 (28 consecutive days) and UAS84 (84 consecutive days), require complete daily documentation.
The AAS is a validated PROM tool for patients with predominant angioedema (with or without wheals) to self-evaluate disease activity. It also helps the treating physician to assess treatment success. The AAS is based on a daily questionnaire recording the number of symptomatic days and swelling intensity summed to give a daily score.
Lower scores and higher scores represent low and high disease activity, respectively. AAS7, AAS28, and AAS84 describe the disease activity of 7, 28, and 84 consecutive days. As symptoms often change in intensity, it is essential that patients document them for several consecutive days using the AAS in order to determine the overall disease activity.
The AAS7 requires complete documentation for 7 consecutive days, as this is what makes assessment of disease activity possible. For a more detailed and comprehensive assessment of disease activity, the AAS28 (28 consecutive days) and AAS84 (84 consecutive days) require complete daily documentation.
Symptoms Control
Urticaria Control Test (UCT) & Angioedema Control Test (AECT)
Both Urticaria Control Test (UCT) & Angioedema Control Test (AECT) were developed specifically to assess the control status and therapeutic response of chronic urticaria.
The UCT is a validated PROM tool for patients with chronic urticaria to self-evaluate disease control. It is based on a questionnaire recording the impact of the current therapy on disease activity referring to a recall period of the past 7 days or to the past 4 weeks prior to evaluation.
The UCT evaluation works on a 16-point scale to help to distinguish patients with poorly controlled urticaria (less than 12 points) from patients with well controlled disease (12 points or more).
The AECT is a validated PROM tool for patients with predominant angioedema (with or without wheals) to self-evaluate disease control. It is based on a questionnaire recording the impact of the current therapy on disease activity referring to a recall period of the past 4 weeks or to the past 3 months prior to evaluation.
The AECT evaluation works on a 16-point scale to help to distinguish patients with poorly controlled recurrent angioedema (less than 10 points) from patients with well controlled disease (10 points or more).
UCT Video (English)
UCT Video ( German/Deutsch)
UCT Video (Deutsch)
Quality of Life
Chronic Urticaria Quality of Life Questionnaire (CUQ2oL) & Angioedema Quality of Life Questionnaire (AEQoL)
The CU-Q2oL is a validated PROM tool for patients with chronic urticaria to self-evaluate the impact of disease activity and treatments on their wellbeing. It is based on a 23-item questionnaire referring to a recall period of the past 2 weeks prior to evaluation.
The minimum total score is 23. Higher values reflect greater impairment of the symptom-specific health-related quality of life.
The AE-QoL is a validated PROM tool for patients with predominant angioedema (with or without wheals) to self-evaluate the impact of disease activity and treatments on their wellbeing. It is based on a 17-item questionnaire referring to a recall period of the past 4 weeks prior to evaluation.
The total score is transformed into a linear scale from 0 to 100, with higher values reflecting greater impairment of the symptom-specific health-related quality of life.
The CRUSE® app
What is the CRUSE® app?
CRUSE® stands for ChRonic Urticaria Self Evaluation
CRUSE® is a mobile health app developed by renowned dermatologists and allergologists of the UCARE-Team to help chronic urticaria patients track and manage their condition.
The CRUSE® advantage for patients and physicians
• Enables patients to fill out their PROMs daily on their smart device
• Promotes continued monitoring and documentation of CSU disease activity and control
• Reminds patients to monitor their quality of life through push notification
• Allows patients to send a comprehensive report to their treating physician via Email, QR or other platforms
• Educates patients with a comprehensive patient information platform
• Contributes to the understanding of urticaria
CRUSE® helps you and your doctor to track disease activity, how you are responding to treatment and how it can be improved. CRUSE® can do all this and much more. The basis for this are the daily questions based on the so-called PROMs. CRUSE® incorporates the PROM tools UAS, AAS, UCT, and AECT and makes it easy to answer the daily questions allowing you to do this on your mobile device instead of paper.
Please remember that CRUSE® can help to drive urticaria research and enable the development of novel innovative therapeutic approaches with your help by completing the daily questions on CRUSE® as accurately as possible. Your documentation makes a massive impact.
Find out more on www.cruse-control.com
Learn about how healthcare apps change your doctor’s appointment.
Learn more about CRUSE as your pioneer daily companion by listening to episode 35 of “All Things Urticaria” podcast via Spotify or via Apple Podcast.
Note on translations: If you are reading this website in a language other than English, it has been auto-translated to your language, unless otherwise stated at the bottom of each page. If you think the translation is inaccurate, please contact us, and we will be happy to review the translation.
